A tirzepatide review: what clinical trials and real-world use reveal

What made tirzepatide different enough to warrant its own review?

Most weight-loss medicines before tirzepatide worked on a single gut-hormone pathway. Tirzepatide does something structurally different: it binds simultaneously to receptors for two incretin hormones, GIP and GLP-1, both of which are involved in appetite signalling, blood-sugar regulation and the rate at which food leaves the stomach. The question researchers wanted to answer was whether stimulating two pathways produced meaningfully better outcomes than one. The SURMOUNT programme set out to find out.

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. After 72 weeks, participants on 15mg tirzepatide had lost an average of around 20–21% of their starting body weight. To put that in context, tirzepatide's mechanism and licensed indications are covered in more depth elsewhere, but no other approved weight-management medicine had reached that average in a phase 3 trial at the time. The paper was published in the New England Journal of Medicine and remains the primary evidence base for UK regulatory decisions.

Treatment starts at 2.5mg (a dose chosen because it allows the body to adjust before any therapeutic increase) and is titrated by the prescriber, typically in four-week steps, through 5, 7.5, 10, 12.5 and up to 15mg. The prescriber, not the patient, decides the pace.

Does the head-to-head evidence hold up against semaglutide?

The natural follow-up question for anyone reading a tirzepatide review article is how it compares to semaglutide, which had previously set the benchmark. SURMOUNT-5, published in the New England Journal of Medicine in 2025, ran for 72 weeks and enrolled 751 adults with obesity but without diabetes. Participants received either tirzepatide or semaglutide 2.4mg. Tirzepatide produced greater average weight loss across the trial period.

Two caveats matter here. First, SURMOUNT-5 was open-label rather than blinded, which limits how definitively conclusions can be drawn. Second, Novo Nordisk has since received MHRA approval for a 7.2mg semaglutide dose, with trials reporting around 20.7% average loss over 72 weeks, a result that narrows the gap considerably. The honest position, which NICE's appraisal of tirzepatide (TA1026) also acknowledges, is that indirect comparisons favour tirzepatide but the margin is not fixed. Which medicine suits a particular person is a clinical question, not a trial-averages question.

For a broader look at how patients and prescribers describe real-world use, the Mounjaro review page covers experience alongside the trial data.

What does a tirzepatide review reveal about the side-effect profile?

The side effects that appear most consistently across tirzepatide trials are gastrointestinal. Nausea leads the list, followed by diarrhoea, constipation and indigestion; some people also notice fatigue or a mild headache during dose-increase weeks. These effects are most noticeable shortly after starting or after a dose step up, and they tend to settle within days to a couple of weeks as the body adjusts.

In January 2026 the MHRA issued a Drug Safety Update specifically addressing acute pancreatitis as an infrequent but serious risk with GLP-1 class medicines. Severe, persistent stomach pain that extends towards the back (especially alongside vomiting) warrants urgent medical attention rather than a wait-and-see approach. Any suspected side effect can be reported to the MHRA's Yellow Card scheme, which is how post-market safety signals reach regulators.

Tirzepatide carries a Black Triangle (▼) designation in the UK, meaning it is subject to additional MHRA monitoring. That does not imply it is unsafe; it reflects its relatively recent approval and the requirement to gather ongoing real-world data.

For anyone weighing the financial side of starting treatment, the Mounjaro cost page lays out what private pricing typically covers and why the headline number rarely tells the whole story.

Who does the evidence apply to, and are there gaps?

SURMOUNT-1 recruited adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. NICE's recommendation (TA1026) is anchored to a BMI of 35 or higher with at least one relevant comorbidity for NHS access, though lower thresholds apply for some ethnic backgrounds under UK guidance, and private prescribing follows the licensed indications more broadly.

Several populations were specifically excluded from the pivotal trials: people who were pregnant, breastfeeding or actively trying to conceive; those under 18; and people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. These exclusions are reflected in the licence, not as precautions added later.

There is also a practical limitation worth noting in any honest review: trial participants receive structured support, consistent follow-up and controlled conditions. Real-world weight loss averages tend to be somewhat lower, though they remain clinically meaningful. A one-minute check worth doing before reading any review is confirming the source: the GPhC register at pharmacyregulation.org lets you verify whether a UK pharmacy publishing treatment reviews is actually registered to dispense. Unregistered sources have no obligation to publish accurate clinical information.

The tirzepatide patient review section and Mounjaro articles archive collect further reading if you want to explore specific aspects of treatment in more depth, and if you are specifically interested in what people taking the tablet form of this medicine have said, the oral tirzepatide reviews page brings together that first-hand experience in one place. If you have read enough to want to know whether tirzepatide is suitable for you personally, the right next step is a clinical assessment rather than more browsing. Our prescribers review every consultation the same day it arrives.